Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyWashington HCA Urinalysis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentWashington State Health Care AuthorityPolicy N/A

    Urinalysis Drug Testing for Substance Use Disorder Treatment

    Customize your policy alerts

    Sign up for all Washington State Health Care Authority policy alerts

    Know when Washington State Health Care Authority releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Guidance for coverage of urinalysis drug screening and confirmation testing for Apple Health members receiving medication for substance use disorder or formal substance use disorder treatment; excludes workplace and court-ordered or diversion-program testing.

    Policy Summary
    PayerWashington State Health Care Authority
    PolicyUrinalysis Drug Testing for Substance Use Disorder Treatment
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the medical-necessity rationale for each drug screen or urinalysis, including its clinical purpose and ordering provider.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7Maximum drug classes tested at once
    2Qualifying clinical purposes
    TapersTesting frequency during treatment
    1Clinical snapshot represented by urine testing

    Medical Necessity and Coverage Criteria

    Medically Necessary Drug Screening

    Drug screens and urinalysis testing are covered only when medically necessary under WAC 182-500-0070.

    ALL of the following

    • The testing is performed as part of medication management for treatment of a substance use disorder or formal substance use disorder treatment.

    • ONE of the following

      • The drug screen is ordered by a prescribing provider as part of a medical evaluation.
      • The drug screen is necessary to assess suitability for medical tests or treatment.

    Drug or Metabolite Presence Testing

    Testing for the presence or absence of a drug or its metabolite may be medically necessary when it supports therapeutic compliance.

    ALL of the following

    • The test is performed in connection with treatment for a substance use disorder or formal substance use disorder treatment.
    • The test evaluates the presence or absence of a drug or metabolite to assure compliance with a therapeutic intervention.
    • The testing is clinically relevant to the individual's treatment and meets medical-necessity requirements.

    Confirmatory Testing After a Negative Screen

    Confirmatory testing after a negative presumptive screen is covered only when the clinical record supports medical necessity.

    ALL of the following

    • A presumptive screen is negative.
    • The individual has clinical signs or symptoms suggesting active drug use.
    • The clinical signs or symptoms and the reason for confirmatory testing are documented in the medical record.

    Testing performed solely to monitor compliance with a court order is not part of the medical or behavioral health Apple Health benefit. Apple Health does not reimburse drug screens or urinalysis confirmation testing required by pre-trial, probation, diversion, or other criminal-justice compliance programs unless additional clinical indicators support medical necessity.

    This guidance does not apply to individuals participating in a court-ordered or diversion program, individuals enrolled in a therapeutic court and ordered to participate in chemical-dependency treatment, or workplace drug testing. Tests for therapeutic-court participants are ordered and paid for by the criminal court system. For court- or compliance-required testing, other funding sources must be used, such as county behavioral health taxes, client participation fees, substance-abuse block grants, or criminal-justice treatment account dollars.

    Testing drug levels to determine whether diversion or urine adulteration is occurring is not a medical intervention and is not medically necessary. Such testing is therefore not covered, even when performed in connection with substance use disorder treatment.

    There is no support for immunoassay or mass-spectrometry testing of more than seven individual drug classes at one time, based on statewide prescription-monitoring-program reports and seizure information.

    High ethyl glucuronide levels reflect recent alcohol use, but low cutoff levels may be falsely negative for lower levels of alcohol use. Several substances can also produce false-positive ethyl glucuronide results, limiting the reliability and accuracy of conclusions applied to patient care.

    When persistent evidence of alcohol use exists despite treatment for alcohol use disorder, consider increasing treatment intensity rather than relying on ethyl glucuronide results alone.

    Quantitative drug testing is not reliably predictive of patterns of use because hydration status, diurnal variability, metabolic rate, and time since last ingestion can affect drug levels and metabolite levels.

    No agreed-upon norbuprenorphine-to-buprenorphine ratio has been validated across large sample sizes or diverse populations to establish an appropriate threshold for ruling out diversion. Ratio results should not be used as a standalone basis to determine diversion.

    Drug screens and urinalysis testing fail medical-necessity requirements when they are not ordered by a prescribing provider as part of a medical evaluation and are not necessary to assess suitability for medical tests or treatment. Testing solely for workplace purposes, court or criminal-justice compliance, diversion-program requirements, or therapeutic-court requirements is outside this coverage guidance unless additional clinical indicators support medical necessity.

    Drug-level testing intended to identify diversion or urine adulteration is not covered because it is not a medical intervention and does not meet medical-necessity requirements.

    Coding and Utilization Parameters

    Individual drug classes tested at once
    Maximum supportedNo more than 7 individual drug classes may be tested at once.
    Applicable methodsThe limit applies to immunoassay and mass spectrometry testing.
    Coverage positionTesting more than 7 individual drug classes at once is not supported by this guidance.

    Provider Documentation and Action Items

    Documentation Required

    Document the medical-necessity rationale

    Document the medical-necessity rationale for the drug screen or urinalysis, including that it was ordered as part of a medical evaluation or was necessary to assess suitability for a medical test or treatment.

    Documentation Required

    Support confirmation after a negative screen

    For confirmatory testing performed after a negative presumptive screen, document clinical signs or symptoms suggesting active drug use to establish medical necessity.

    Documentation Required

    Interpret results clinically

    When testing is used to support treatment decisions, interpret the results in the context of the person’s functional status and treatment response.

    • Continued use with no functional improvement may support consideration of a higher level of care or more intensive services.
    Denial Risk

    Do not bill Apple Health for compliance-only testing

    Testing is not reimbursed when performed solely to monitor compliance with a court order, pre-trial requirement, probation, or diversion program unless additional clinical indicators support medical necessity.

    • Use other non-Apple Health funding for court or compliance-required testing when medical-necessity criteria are not met.
    Denial Risk

    Recognize excluded testing settings

    Workplace drug testing and testing ordered for people participating in therapeutic court or other court-ordered chemical dependency treatment are outside this guidance and are not payable under the Apple Health medical benefit.

    Billing Rule

    Limit simultaneous drug-class testing

    Do not perform immunoassay or mass spectrometry testing of more than seven individual drug classes at one time; testing above this limit is not supported by the guidance.

    • Maximum supported at one time: 7 individual drug classes.
    Denial Risk

    Do not use testing solely to assess diversion or adulteration

    Testing drug levels to determine whether diversion or urine adulteration is occurring is not a medical intervention and is not considered medically necessary.

    Denial Risk

    Document clinical support for negative-screen confirmation

    Confirmatory testing after a negative presumptive screen requires documentation of clinical signs or symptoms suggesting active use to establish medical necessity. Without that clinical documentation, the testing may be denied.

    Clinical Context

    Urine drug testing provides a time-limited snapshot of drug or metabolite presence or absence at a particular point in time. A result is not, by itself, diagnostic of a substance use disorder and should be interpreted with the person's clinical condition and treatment response.

    Key Definitions

    Urine drug testing
    What it measuresA urine drug test reflects the presence or absence of a drug or metabolite at a particular point in time.
    Clinical limitationThe result represents a moment in time and is not, by itself, diagnostic of a substance use disorder.
    Use in careResults should be considered in the context of the individual's treatment and clinical status.
    Medical necessity
    Applicable definitionMedical necessity is defined in WAC 182-500-0070.
    Ordering requirementThe drug screen must be ordered by a prescribing provider as part of a medical evaluation, or be necessary to assess suitability for medical tests or treatment.
    Coverage requirementDrug screening and urinalysis testing must meet medical-necessity criteria for Apple Health reimbursement.
    Presumptive and confirmatory testing
    Presumptive testA presumptive test is the initial drug screen.
    Confirmatory testA confirmatory test is performed to further evaluate a presumptive result.
    After a negative screenConfirmatory testing after a negative presumptive screen requires documented clinical signs or symptoms suggesting active use to establish medical necessity.

    Covered Clinical Indications

    Medication Management or Formal Substance Use Disorder Treatment

    Testing may be covered for an Apple Health member receiving medication or formal treatment for substance use disorder when it serves a qualifying medical purpose.

    Qualifying indication and medical necessity

    • The individual has Apple Health coverage and is receiving medication for substance use disorder or formal substance use disorder treatment.

    • Qualifying clinical purpose

      • The test is ordered by a prescribing provider as part of a medical evaluation.
      • The test is necessary to assess suitability for medical tests or treatment.

    Assessing Drug or Metabolite Presence or Absence for Therapeutic Compliance

    Testing may be medically necessary when it evaluates drug or metabolite presence or absence to support adherence to treatment.

    Covered therapeutic-intervention monitoring

    • The test assesses the presence or absence of a drug or its metabolite to assure compliance with a therapeutic intervention.
    • The testing is used to support the therapeutic intervention rather than to determine whether diversion or urine adulteration is occurring.

      Testing drug levels for diversion or urine adulteration is not a medical intervention and is not medically necessary.

    Testing Limits and Expected Utilization

    Multiple-drug-class testing
    Maximum per testing eventNo more than 7 individual drug classes may be tested simultaneously.
    Testing methodsThe limit applies to immunoassay or mass spectrometry testing.
    Evidence supportThere is no support for testing more than 7 individual drug classes at once under this guidance.
    Point-of-care and confirmatory urine drug testing
    Initial treatmentPoint-of-care and confirmatory testing frequency and utilization are expected to be higher during the initial stages of treatment.
    Over timeTesting frequency and utilization are expected to taper off over time.
    Clinical contextUrine drug testing reflects a moment in time and is not by itself diagnostic of a substance use disorder.

    Ordering Requirements

    Documentation Required

    Ensure the required provider orders the test

    Drug screens must be ordered by a prescribing provider as part of a medical evaluation or be necessary to assess suitability for medical tests or treatment.

    • The test must also meet medical-necessity criteria.

    Noncovered Services

    The Apple Health medical benefit does not cover testing performed solely for court-ordered, pre-trial, probation, diversion, or therapeutic-court compliance without additional clinical indicators supporting medical necessity. Therapeutic-court chemical-dependency treatment testing is ordered and paid for by the criminal court system. Workplace drug testing is also outside this guidance.

    Policy Summary
    PayerWashington State Health Care Authority
    PolicyUrinalysis Drug Testing for Substance Use Disorder Treatment
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the medical-necessity rationale for each drug screen or urinalysis, including its clinical purpose and ordering provider.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Utilization ParametersProvider Documentation and Action ItemsClinical ContextKey DefinitionsCovered Clinical IndicationsTesting Limits and Expected UtilizationOrdering RequirementsNoncovered Services

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.